clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Chlamydial Pneumonia D061387 2 associated lipids
Sacroiliitis D058566 1 associated lipids
Plaque, Atherosclerotic D058226 7 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Upper Extremity Deep Vein Thrombosis D056824 1 associated lipids
Leprosy, Paucibacillary D056005 2 associated lipids
Extensively Drug-Resistant Tuberculosis D054908 1 associated lipids
Buruli Ulcer D054312 1 associated lipids
Immune Reconstitution Inflammatory Syndrome D054019 1 associated lipids
Renal Insufficiency D051437 8 associated lipids
Desulfovibrionaceae Infections D045824 5 associated lipids
Chlamydophila Infections D023521 4 associated lipids
Epilepsy, Partial, Motor D020938 1 associated lipids
Central Nervous System Protozoal Infections D020808 3 associated lipids
Neurotoxicity Syndromes D020258 34 associated lipids
Genetic Predisposition to Disease D020022 24 associated lipids
alpha 1-Antitrypsin Deficiency D019896 3 associated lipids
Tooth, Nonvital D019553 2 associated lipids
Gingival Overgrowth D019214 7 associated lipids
Carcinoma, Lewis Lung D018827 22 associated lipids
Cryptogenic Organizing Pneumonia D018549 3 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Soft Tissue Infections D018461 2 associated lipids
Pneumonia, Bacterial D018410 16 associated lipids
Cardiovascular Abnormalities D018376 2 associated lipids
Tuberculosis, Multidrug-Resistant D018088 6 associated lipids
Cytomegalovirus Retinitis D017726 2 associated lipids
Community-Acquired Infections D017714 8 associated lipids
Soft Tissue Injuries D017695 2 associated lipids
Periodontal Attachment Loss D017622 7 associated lipids
Kleine-Levin Syndrome D017593 1 associated lipids
Cutaneous Fistula D017577 1 associated lipids
Pityriasis Rosea D017515 3 associated lipids
Dermatitis, Phototoxic D017484 4 associated lipids
Skin Diseases, Bacterial D017192 8 associated lipids
Liver Failure, Acute D017114 11 associated lipids
IgA Deficiency D017098 2 associated lipids
AIDS-Related Opportunistic Infections D017088 9 associated lipids
Common Variable Immunodeficiency D017074 4 associated lipids
Meningitis, Bacterial D016920 6 associated lipids
Angiomatosis, Bacillary D016917 2 associated lipids
Gram-Negative Bacterial Infections D016905 16 associated lipids
Ureaplasma Infections D016869 5 associated lipids
Empyema, Pleural D016724 2 associated lipids
Still's Disease, Adult-Onset D016706 2 associated lipids
Purpura, Thrombocytopenic, Idiopathic D016553 4 associated lipids
Bronchial Hyperreactivity D016535 15 associated lipids
Helicobacter Infections D016481 21 associated lipids
Bacteremia D016470 9 associated lipids
Prosthesis-Related Infections D016459 7 associated lipids
Lymphoma, T-Cell, Cutaneous D016410 4 associated lipids
Eye Infections, Bacterial D015818 3 associated lipids
Eye Infections D015817 1 associated lipids
Eye Injuries, Penetrating D015807 2 associated lipids
Leprosy, Lepromatous D015440 2 associated lipids
Leprosy, Borderline D015439 3 associated lipids
Discitis D015299 2 associated lipids
Mycobacterium avium-intracellulare Infection D015270 4 associated lipids
Sexually Transmitted Diseases, Bacterial D015231 5 associated lipids
Wound Infection D014946 12 associated lipids
Whooping Cough D014917 6 associated lipids
Uveitis, Anterior D014606 11 associated lipids
Urticaria D014581 13 associated lipids
Urination Disorders D014555 9 associated lipids
Urinary Tract Infections D014552 11 associated lipids
Urethritis D014526 9 associated lipids
Ureteral Obstruction D014517 10 associated lipids
Ureteral Diseases D014515 3 associated lipids
Typhoid Fever D014435 2 associated lipids
Tuberculosis, Spinal D014399 1 associated lipids
Tuberculosis, Pulmonary D014397 18 associated lipids
Tuberculosis, Ocular D014392 1 associated lipids
Tuberculosis, Avian D014379 2 associated lipids
Tuberculosis D014376 20 associated lipids
Tooth Discoloration D014075 7 associated lipids
Tenosynovitis D013717 3 associated lipids
Syphilis D013587 6 associated lipids
Synovitis D013585 15 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Stomach Ulcer D013276 75 associated lipids
Stomach Neoplasms D013274 24 associated lipids
Stomach Diseases D013272 7 associated lipids
Sporotrichosis D013174 3 associated lipids
Splenic Diseases D013158 5 associated lipids
Skin Ulcer D012883 6 associated lipids
Skin Neoplasms D012878 12 associated lipids
Skin Diseases, Infectious D012874 7 associated lipids
Sinusitis D012852 9 associated lipids
Shock, Septic D012772 11 associated lipids
Serositis D012700 1 associated lipids
Scrub Typhus D012612 3 associated lipids
Rosacea D012393 13 associated lipids
Rodent Diseases D012376 4 associated lipids
Rickettsia Infections D012282 5 associated lipids
Rhabdomyolysis D012206 9 associated lipids
Radiation Injuries D011832 14 associated lipids
Pyelonephritis D011704 5 associated lipids
Psychoses, Substance-Induced D011605 7 associated lipids
Psychophysiologic Disorders D011602 3 associated lipids
Psoriasis D011565 47 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Stephenson GA et al. Solid-state investigations of erythromycin A dihydrate: structure, NMR spectroscopy, and hygroscopicity. 1997 J Pharm Sci pmid:9383733
Villanueva A et al. Report on an outbreak of postinjection abscesses due to Mycobacterium abscessus, including management with surgery and clarithromycin therapy and comparison of strains by random amplified polymorphic DNA polymerase chain reaction. 1997 Clin. Infect. Dis. pmid:9195073
Gabl M et al. Flexor tenosynovitis in the hand caused by Mycobacterium malmoense: a case report. 1997 J Hand Surg Am pmid:9195437
Rubin BK et al. Effect of clarithromycin on nasal mucus properties in healthy subjects and in patients with purulent rhinitis. 1997 Am. J. Respir. Crit. Care Med. pmid:9196110
Rodvold KA et al. Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers. 1997 Antimicrob. Agents Chemother. pmid:9174209
Lo WC et al. Clarithromycin in the combination therapy for the eradication of Helicobacter pylori in peptic ulcer disease. 1997 Zhonghua Yi Xue Za Zhi (Taipei) pmid:9198292
Fréhel C et al. The phagosomal environment protects virulent Mycobacterium avium from killing and destruction by clarithromycin. 1997 Infect. Immun. pmid:9199452
Marignani M et al. Reversal of long-standing iron deficiency anaemia after eradication of Helicobacter pylori infection. 1997 Scand. J. Gastroenterol. pmid:9200297
Kato S et al. Omeprazole-based dual and triple regimens for Helicobacter pylori eradication in children. 1997 Pediatrics pmid:9200377
Woo MS et al. Pediatric transplant grand rounds. A case presentation: skin lesions in a post-lung transplant patient. 1997 Pediatr Transplant pmid:10084776
Gisbert JP et al. [What is the current role of clarithromycin in the eradication of Helicobacter pylori?]. 1997 Rev Esp Enferm Dig pmid:9221019
Matsumoto T et al. Regression of mucosa-associated lymphoid-tissue lymphoma of rectum after eradication of Helicobacter pylori. 1997 Lancet pmid:9228971
Kadayifçi A et al. Clarithromycin-induced fever in a patient with Helicobacter pylori gastritis. 1997 Ann Pharmacother pmid:9184727
Götz JM et al. Treatment of Helicobacter pylori infection favourably affects gastric mucosal superoxide dismutases. 1997 Gut pmid:9203935
Katari SR et al. Clinical features of acute reversible tacrolimus (FK 506) nephrotoxicity in kidney transplant recipients. 1997 Clin Transplant pmid:9193849
Waites K et al. In vitro activities of oral antimicrobial agents against penicillin-resistant Streptococcus pneumoniae: implications for outpatient treatment. 1997 South. Med. J. pmid:9191739
Rodrigues AD et al. Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily. 1997 Drug Metab. Dispos. pmid:9152603
Garrison MW et al. Influence of pH on the antimicrobial activity of clarithromycin and 14-hydroxyclarithromycin against Haemophilus influenzae using an in vitro pharmacodynamic model. 1997 Diagn. Microbiol. Infect. Dis. pmid:9154410
Nightingale CH Pharmacokinetics and pharmacodynamics of newer macrolides. 1997 Pediatr. Infect. Dis. J. pmid:9109156
Block SL Causative pathogens, antibiotic resistance and therapeutic considerations in acute otitis media. 1997 Pediatr. Infect. Dis. J. pmid:9109158
Tarlow MJ et al. Future indications for macrolides. 1997 Pediatr. Infect. Dis. J. pmid:9109159
Rodrigo Sáez L et al. [The efficacy of using a short course of 6-day duration (OCA-6) in the treatment to eradicate Helicobacter pylori infection. Omeprazole, clarithromycin, amoxicillin]. 1997 Rev Esp Enferm Dig pmid:9115827
Reed PI and Johnston BJ Treatment of Helicobacter pylori infection. 1997 Biomed. Pharmacother. pmid:9084725
Plemmons RM et al. Osteomyelitis due to Mycobacterium haemophilum in a cardiac transplant patient: case report and analysis of interactions among clarithromycin, rifampin, and cyclosporine. 1997 Clin. Infect. Dis. pmid:9142810
Khan AA et al. Activity of trovafloxacin in combination with other drugs for treatment of acute murine toxoplasmosis. 1997 Antimicrob. Agents Chemother. pmid:9145840
Collins L and Franzblau SG Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. 1997 Antimicrob. Agents Chemother. pmid:9145860
Lounis N et al. Comparative activities of amikacin against Mycobacterium avium complex in nude and beige mice. 1997 Antimicrob. Agents Chemother. pmid:9145892
Spinzi G et al. Randomized study comparing omeprazole plus amoxycillin versus omeprazole plus clarithromycin for eradication of Helicobacter pylori. 1997 Aliment. Pharmacol. Ther. pmid:9146769
Peterson WL The role of antisecretory drugs in the treatment of Helicobacter pylori infection. 1997 Aliment. Pharmacol. Ther. pmid:9146787
Fischbach W et al. Regression of immunoproliferative small intestinal disease after eradication of Helicobacter pylori. 1997 Lancet pmid:8988128
Walzer PD et al. Clinically used antimicrobial drugs against experimental pneumocystosis, singly and in combination: analysis of drug interactions and efficacies. 1997 Antimicrob. Agents Chemother. pmid:9021174
Banerjee DK et al. Experimental evaluation of possible new short-term drug regimens for treatment of multibacillary leprosy. 1997 Antimicrob. Agents Chemother. pmid:9021187
Paar D et al. Life-threatening interaction between clarithromycin and disopyramide. 1997 Lancet pmid:9024381
Wang XM et al. [Time course of disappearance of Helicobacter pylori after topical therapy and new triple therapy]. 1997 Nihon Shokakibyo Gakkai Zasshi pmid:9028149
Macías J et al. Rhodococcus or mycobacterium? An example of misdiagnosis in HIV infection. 1997 AIDS pmid:9030376
Rouse MS et al. Efficacy of azithromycin or clarithromycin for prophylaxis of viridans group streptococcus experimental endocarditis. 1997 Antimicrob. Agents Chemother. pmid:9257739
Burman WJ et al. A retrospective comparison of clarithromycin versus rifampin in combination treatment for disseminated Mycobacterium avium complex disease in AIDS: clarithromycin decreases transfusion requirements. 1997 Int. J. Tuberc. Lung Dis. pmid:9441082
Suzuki K et al. Activity of KRM 1648 or rifabutin alone or in combination with clarithromycin against Mycobacterium avium complex in human alveolar macrophages. 1997 Int. J. Tuberc. Lung Dis. pmid:9441102
Gotoh A et al. Interaction of drugs for eradication therapy against antibiotic-resistant strains of Helicobacter pylori. 1997 Microbiol. Immunol. pmid:9444328
Prattichizzo FA et al. [Carditis associated with Mycoplasma pneumoniae infection. Clinical aspects and therapeutic problems]. 1997 Minerva Cardioangiol pmid:9446067
Genné D et al. Clarithromycin versus amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia. 1997 Eur. J. Clin. Microbiol. Infect. Dis. pmid:9447898
Hoppe JE and Tschirner T Comparison of Etest and agar dilution for testing the activity of three macrolides against Bordetella parapertussis. 1997 Diagn. Microbiol. Infect. Dis. pmid:9218920
Visalli MA et al. Susceptibility of twenty penicillin-susceptible and -resistant pneumococci to levofloxacin, ciprofloxacin, ofloxacin, erythromycin, azithromycin, and clarithromycin by MIC and time-kill. 1997 Diagn. Microbiol. Infect. Dis. pmid:9294703
de'Clari F Ciprofloxacin was the culprit--not itraconazole. 1997 Clin. Infect. Dis. pmid:8994764
Raasveld MH et al. Cat-scratch disease mimicking pancreatic malignancy: case report. 1997 Clin. Infect. Dis. pmid:8994767
Tompkins DS et al. Failed treatment of Helicobacter pylori infection associated with resistance to clarithromycin. 1997 Helicobacter pmid:9421121
Taylor JL et al. Pharmacoeconomic comparison of treatments for the eradication of Helicobacter pylori. 1997 Arch. Intern. Med. pmid:8996045
Hultén K et al. Combination treatment with ranitidine is highly efficient against Helicobacter pylori despite negative impact of macrolide resistance. 1997 Helicobacter pmid:9421122
Drugs for treatment of peptic ulcers. 1997 Med Lett Drugs Ther pmid:8996458
O'Connor HJ et al. One week triple therapy for Helicobacter pylori: does high-dose clarithromycin confer additional benefit? 1997 Helicobacter pmid:9421124
Matsunaga K et al. [Successful eradication of H. pylori in an elderly patient with gastric cancer after effective UFT-E therapy]. 1997 Gan To Kagaku Ryoho pmid:9422074
Stone GG et al. A PCR-oligonucleotide ligation assay to determine the prevalence of 23S rRNA gene mutations in clarithromycin-resistant Helicobacter pylori. 1997 Antimicrob. Agents Chemother. pmid:9056021
Moayyedi P et al. Patient factors that predict failure of omeprazole, clarithromycin, and tinidazole to eradicate Helicobacter pylori. 1997 J. Gastroenterol. pmid:9058291
Zuberi BF et al. Low dose, short-term, triple therapy for helicobacter pylori associated peptic ulcer. 1997 J Pak Med Assoc pmid:9361485
Zullo A et al. Omeprazole plus clarithromycin and either tinidazole or tetracycline for Helicobacter pylori infection: a randomized prospective study. 1997 Am. J. Gastroenterol. pmid:9362185
Buckley MJ et al. Metronidazole resistance reduces efficacy of triple therapy and leads to secondary clarithromycin resistance. 1997 Dig. Dis. Sci. pmid:9365144
Misiewicz JJ et al. One week triple therapy for Helicobacter pylori: a multicentre comparative study. Lansoprazole Helicobacter Study Group. 1997 Gut pmid:9462204
Loo VG et al. In-vitro susceptibility of Helicobacter pylori to ampicillin, clarithromycin, metronidazole and omeprazole. 1997 J. Antimicrob. Chemother. pmid:9462442
Marone P et al. Rapid drug susceptibility of Mycobacterium avium complex using a fluorescence quenching method. 1997 J Chemother pmid:9269603
Hoffner SE et al. In-vitro activity of fluorinated quinolones and macrolides against drug-resistant Mycobacterium tuberculosis. 1997 J. Antimicrob. Chemother. pmid:9462443
Teramoto S et al. [Fluctuation in the cytokine m-RNA content in primary non-small cell lung cancer caused by clarithromycin (CAM) administration]. 1997 Jpn J Antibiot pmid:9597438
Torresani C et al. Clarithromycin versus doxycycline in the treatment of rosacea. 1997 Int. J. Dermatol. pmid:9466207
Mikasa K et al. [Effect of clarithromycin on prolonging the life expectancy of patients with primary lung cancer]. 1997 Jpn J Antibiot pmid:9597439
Takeda H et al. [Macrolide antibiotic actions on bacteria and cultured airway cells]. 1997 Jpn J Antibiot pmid:9597448
Mita Y et al. [Vitamin D3 induction of differentiation of HL-60 cells to monocyte- like cells and their aggregation--a dynamic culture method and clarithromycin]. 1997 Jpn J Antibiot pmid:9597462
Yanagihara K et al. [Analysis of chronic respiratory tract infection by using an intubation model--evaluation based on fluctuations in cytokine content]. 1997 Jpn J Antibiot pmid:9597463
Nilius AM et al. Variability in susceptibilities of Haemophilus influenzae to clarithromycin and azithromycin due to medium pH. 1997 J. Clin. Microbiol. pmid:9163435
Konishi M et al. [Log-term administration of clarithromycin as a possible adjuvant therapy of HIV infections]. 1997 Jpn J Antibiot pmid:9597467
Boixeda de Miquel D [Efficacy of the triple therapy in the eradication of H. pylori in peptic ulcer]. 1997 Rev Esp Enferm Dig pmid:9494374
Pérez Mota A et al. Helicobacter pylori, efficacy of the new triple therapy in six and twelve-day schedules. 1997 Rev Esp Enferm Dig pmid:9494375
Payen MC et al. [Manifestations, diagnosis and treatment of non-tuberculous mycobacterial infections in patients with HIV infection]. 1997 Rev Mal Respir pmid:9496599
Price J and Hamilton W Pragmatic eradication of H. pylori. 1997 Br J Gen Pract pmid:9474836
Tarlow MJ Macrolides in the management of streptococcal pharyngitis/tonsillitis. 1997 Pediatr. Infect. Dis. J. pmid:9109157
Dubé MP et al. A randomized evaluation of ethambutol for prevention of relapse and drug resistance during treatment of Mycobacterium avium complex bacteremia with clarithromycin-based combination therapy. California Collaborative Treatment Group. 1997 J. Infect. Dis. pmid:9359722
Uemura N et al. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. 1997 Cancer Epidemiol. Biomarkers Prev. pmid:9264278
Misiewicz JJ Management of Helicobacter pylori-related disorders. 1997 Eur J Gastroenterol Hepatol pmid:9160212
Mor N and Esfandiari A Synergistic activities of clarithromycin and pyrazinamide against Mycobacterium tuberculosis in human macrophages. 1997 Antimicrob. Agents Chemother. pmid:9303411
Savarino V et al. A new 1-week therapy for Helicobacter pylori eradication: ranitidine bismuth citrate plus two antibiotics. 1997 Aliment. Pharmacol. Ther. pmid:9305478
Williams MP et al. Seven-day treatment for Helicobacter pylori infection: ranitidine bismuth citrate plus clarithromycin and tetracycline hydrochloride. 1997 Aliment. Pharmacol. Ther. pmid:9305479
Hultén K et al. Macrolide resistance in Helicobacter pylori: mechanism and stability in strains from clarithromycin-treated patients. 1997 Antimicrob. Agents Chemother. pmid:9371366
Sánchez-Nuñez ML et al. Clarithromycin in the treatment of cyclosporin-associated gingival hyperplasia. 1997 Nephrol. Dial. Transplant. pmid:9306384
Finkenbine R and Gill HS Case of mania due to prednisone-clarithromycin interaction. 1997 Can J Psychiatry pmid:9307841
Gisbert JP et al. Unhealed duodenal ulcers despite Helicobacter pylori eradication. 1997 Scand. J. Gastroenterol. pmid:9246702
Fuursted K Evaluation of the post-antibiotic effect of six anti-mycobacterial agents against Mycobacterium avium by the Bactec radiometric method. 1997 J. Antimicrob. Chemother. pmid:9249202
Böttger EC et al. Prophylaxis of mycobacterial infection and acquired drug resistance. 1997 J. Antimicrob. Chemother. pmid:9249224
Peloquin CA and Berning SE Advice on treatment of Mycobacterium avium complex infection. 1997 Am J Health Syst Pharm pmid:9161632
Walsh D et al. One week treatment for Helicobacter pylori infection. 1997 Arch. Dis. Child. pmid:9166031
Tillenburg B et al. [Helicobacter pylori: pretherapeutic resistance status in Germany (Ruhr area)]. 1997 Z Gastroenterol pmid:9173687
Suzuki Y et al. [Antimicrobial activities of clarithromycin against recent obtained clinical isolates]. 1997 Jpn J Antibiot pmid:9394238
Ando H et al. [Changes in serum anti-Helicobacter pylori IgG antibody, pepsinogen I, and pepsinogen II after eradication therapy of Helicobacter pylori]. 1997 Nihon Shokakibyo Gakkai Zasshi pmid:9396326
Veldhuyzen van Zanten SJ et al. Helicobacter pylori: new developments and treatments. 1997 CMAJ pmid:9176424
Nakao K et al. Relation of lactoferrin levels in gastric mucosa with Helicobacter pylori infection and with the degree of gastric inflammation. 1997 Am. J. Gastroenterol. pmid:9177520
Langtry HD and Brogden RN Clarithromycin. A review of its efficacy in the treatment of respiratory tract infections in immunocompetent patients. 1997 Drugs pmid:9179528
Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group. 1997 Gut pmid:9274464
Lam SK et al. Does treatment of Helicobacter pylori with antibiotics alone heal duodenal ulcer? A randomised double blind placebo controlled study. 1997 Gut pmid:9274470
Kundu S et al. Clarithromycin-induced ventricular tachycardia. 1997 Ann Emerg Med pmid:9326871
Hirakawa T [Diagnosis and treatment of Helicobacter pylori]. 1997 Nippon Ika Daigaku Zasshi pmid:9283206
Meyer JM et al. In vitro synergy testing of clarithromycin and 14-hydroxyclarithromycin with amoxicillin or bismuth subsalicylate against Helicobacter pylori. 1997 Antimicrob. Agents Chemother. pmid:9210696
Chimura T [Measurement of antibody titers to chlamydial infection and effects of levofloxacin in cystic cervicitis and chlamydial infection]. 1997 Jpn J Antibiot pmid:9212369
Lim AG et al. Helicobacter pylori eradication using a 7-day regimen of low-dose clarithromycin, lansoprazole and amoxycillin. 1997 Aliment. Pharmacol. Ther. pmid:9218079